Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The biological association between mTOR activation and AR pathway suggests that there may exist a subgroup of TNBC in which the combination of both AR antagonism and mTOR inhibition should have a synergistic effect on cell growth and tumor progression. 27350136 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE In particular, in ER-positive breast cancer, AR signaling often antagonizes the growth stimulatory effect of ER signaling; in triple-negative breast cancer (TNBC), AR seems to drive tumor progression (at least in luminal AR subtype of TNBC with a gene expression profile mimicking luminal subtypes despite being negative to ER and enriched in AR expression); in HER2-positive breast cancer, in the absence of ER expression, AR signaling has a proliferative role. 27528625 2016
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Immunohistochemistry (IHC) was used to detect AR and G-protein coupled estrogen receptor (GPER) expression in tissue microarrays of 165 TNBC patients. 29059676 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Recent data indicate that the androgen receptor (AR) promotes tumor survival and may serve as a potential therapeutic target in TNBC. 28194662 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We observed a TNBC subtype switch from the luminal androgen receptor to the basal-like subtype at acquired resistance. 28555173 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Immunohistochemical assays were performed to determine the expression of AR in 190 TNBC samples. 28067809 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE HER2<sup>+</sup> and triple-negative breast cancer cell lines were treated with AR antagonist plus anti-HER2 mAb trastuzumab or mTOR inhibitor everolimus. 28468774 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Androgen Receptor Supports an Anchorage-Independent, Cancer Stem Cell-like Population in Triple-Negative Breast Cancer. 28512248 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE Additionally, combination of enzalutamide with BMS-754807 or NVP-AEW541 exerted significant reductions in TNBC proliferation even in cells with low AR expression (<i>p</i> < 0.001). 29099049 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE This review highlights three of these recent trials of AR<sup>+</sup> TNBC and acknowledge ongoing research in this exciting area. 28766215 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. 29069872 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Several molecular targets are being explored to target TNBC including androgen receptor, epidermal growth factor receptor (EGFR), poly(ADP-ribose) polymerase (PARP), and vascular endothelial growth factor (VEGF). 27137076 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Tumoral heterogeneity and the presence of several subtypes of TNBC such as Basal like (BL)-1, BL-2, immune-modulatory, luminal androgen receptor, mesenchymal, and mesenchymal/stem like subtype and claudin low subtype, may explain some of the difficulties faced in managing this challenging disease subgroups. 27456662 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Our study has indicated that the absence of AR might help to identify patients with relatively higher risk of disease relapse and death, and further clinical studies of anti-androgen agents are warranted to enrich the therapeutic strategy options for AR+ TNBCs. 28915596 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE As novel AR-targeting agents are developed and evaluated in clinical trials, it is equally important to establish a robust set of biomarkers for identification of TNBC tumors that are most likely to respond to AR inhibition. 29033586 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Interestingly, AR has been suggested as a potential target candidate in TNBC, while sex hormone levels may regulate the role of AR in BrCa subtypes. 29187427 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE However, the role of ERβ1 in the metastasis of androgen receptor (AR)-positive triple-negative breast cancer (TNBC) and the underlying mechanisms are still unknown. 28583190 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE In this retrospective study we evaluated the prognostic role of 4 different molecular determinants, including androgen receptor (AR), E-cadherin (CDH1), Ki67 index, and basal cytokeratins (CKs) 5/6, in a cohort of 99 patients with TNBC. 29100362 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The combinations of high proliferation, metaplastic features, and immunohistochemical statuses of some EMT and basal-like markers and androgen receptor appeared to be able to characterize the TNBCs that showed cPD after NAC. 28474753 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 AlteredExpression disease BEFREE In triple-negative breast cancer, miRNA expressions are found to be associated with BRCA mutations, immune system, epithelial-mesenchymal transition, cancer stem cell properties and androgen receptor expression. 27439682 2017
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE The androgen receptor (AR) is proposed as a therapeutic target for AR-positive advanced triple-negative breast cancer. 29713287 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Targeting androgen receptor (AR) in TNBC is thought to be a promising approach. 29964098 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Assessing the efficacy of androgen receptor and Sox10 as independent markers of the triple-negative breast cancer subtype by transcriptome profiling. 30279965 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Early data from clinical trials evaluating AR antagonists in invasive/metastatic triple-negative breast cancer suggest that some patients may benefit from androgen blockade. 29489512 2018
Entrez Id: 367
Gene Symbol: AR
AR
0.100 Biomarker disease BEFREE Studies have shown it to antagonize estrogen receptor alpha (ERα) DNA binding, thereby preventing pro-proliferative gene transcription; whilst others have demonstrated AR to take on the mantle of a pseudo ERα particularly in the setting of triple negative breast cancer. 30416486 2018